Literature DB >> 29507793

Clinical diagnosis of malignant pleural mesothelioma.

Andrea Bianco1, Tullio Valente2, Maria Luisa De Rimini3, Giacomo Sica2, Alfonso Fiorelli4.   

Abstract

Malignant pleural mesothelioma (MPM) is a tumour which, despite progress in diagnostic procedures and biomolecular research, has poor prognosis. Symptoms reflect extension of disease and include shortness of breath and chest pain. Unexplained pleural effusion and pleural pain in patients exposed to asbestos should raise the suspicion of MPM. MPM diagnosis requires imaging procedures X-ray and computed tomography (CT) scans; magnetic resonance imaging (MRI) better defines the extension of the tumor while PET scanning provides additional information on metabolic activity, metastases, and response to treatment. Thoracoscopic biopsy remains the most appropriate procedure for definitive diagnosis of mesothelioma. Multimodality treatment including surgery, chemotherapy and radiotherapy has been associated with a better survival in selected patients. Clinical translational research including new approaches targeting immune-checkpoints is opening new horizons which may lead to personalised treatments.

Entities:  

Keywords:  Pleural mesothelioma; clinical diagnosis; malignant pleural mesothelioma (MPM)

Year:  2018        PMID: 29507793      PMCID: PMC5830561          DOI: 10.21037/jtd.2017.10.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  43 in total

Review 1.  Image-based evaluation of tumor response to treatment: where is radiology today?

Authors:  S Kharuzhyk; M Fabel; H von Tengg-Kobligk; H U Kauczor
Journal:  Exp Oncol       Date:  2008-09

2.  Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.

Authors:  Ori Wald; David J Sugarbaker
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

3.  Adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells.

Authors:  Michela Illiano; Ersilia Nigro; Luigi Sapio; Ilaria Caiafa; Annamaria Spina; Olga Scudiero; Andrea Bianco; Sabrina Esposito; Filomena Mazzeo; Paolo Vincenzo Pedone; Aurora Daniele; Silvio Naviglio
Journal:  Pulm Pharmacol Ther       Date:  2017-05-12       Impact factor: 3.410

4.  Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.

Authors:  Frederik L Giesel; Helge Bischoff; Hendrik von Tengg-Kobligk; Marc-André Weber; Christian M Zechmann; Hans-Ulrich Kauczor; Michael V Knopp
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

5.  Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells.

Authors:  J G Ault; R W Cole; C G Jensen; L C Jensen; L A Bachert; C L Rieder
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

6.  Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.

Authors:  Kwan-Chang Kim; Hong-Phuc Vo
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

7.  Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals.

Authors:  D W Kamp; V A Israbian; S E Preusen; C X Zhang; S A Weitzman
Journal:  Am J Physiol       Date:  1995-03

Review 8.  Response evaluation in mesothelioma: Beyond RECIST.

Authors:  Lin Cheng; Nina Tunariu; David J Collins; Matthew D Blackledge; Angela M Riddell; Martin O Leach; Sanjay Popat; Dow-Mu Koh
Journal:  Lung Cancer       Date:  2015-08-22       Impact factor: 5.705

9.  Non-small cell lung cancer evaluated with quantitative contrast-enhanced CT and PET-CT: net enhancement and standardized uptake values are related to tumour size and histology.

Authors:  Luca Brunese; Barbara Greco; Francesca Rosa Setola; Francesco Lassandro; Mario Rosario Guarracino; Marialiusa De Rimini; Sergio Piccolo; Nicolina De Rosa; Roberto Muto; Andrea Bianco; Pietro Muto; Roberto Grassi; Antonio Rotondo
Journal:  Med Sci Monit       Date:  2013-02-07

Review 10.  Fractional exhaled nitric oxide-measuring devices: technology update.

Authors:  Mauro Maniscalco; Carolina Vitale; Alessandro Vatrella; Antonio Molino; Andrea Bianco; Gennaro Mazzarella
Journal:  Med Devices (Auckl)       Date:  2016-06-23
View more
  7 in total

1.  Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research.

Authors:  Eline Janssens; Zoë Mol; Lore Vandermeersch; Sabrina Lagniau; Karim Y Vermaelen; Jan P van Meerbeeck; Christophe Walgraeve; Elly Marcq; Kevin Lamote
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

2.  A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.

Authors:  Hidenori Ando; Masakazu Fukushima; Kiyoshi Eshima; Taichi Hasui; Taro Shimizu; Yu Ishima; Cheng-Long Huang; Hiromi Wada; Tatsuhiro Ishida
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

Review 3.  Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini-review.

Authors:  Yan-Qiu Han; Shang-Cheng Xu; Wen-Qi Zheng; Zhi-De Hu
Journal:  Thorac Cancer       Date:  2020-11-22       Impact factor: 3.500

Review 4.  The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review.

Authors:  Silvia Taralli; Romina Grazia Giancipoli; Carmelo Caldarella; Valentina Scolozzi; Sara Ricciardi; Giuseppe Cardillo; Maria Lucia Calcagni
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

5.  Saved by the Scan: A Case of Early Detection of Sarcomatoid Mesothelioma.

Authors:  Hasan Choudhury; Jason Budde; Nayab Ahmed; Andrew Johnson; Comfort Adewunmi
Journal:  Cureus       Date:  2022-07-12

6.  Sera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies against SV40 Large T Antigen: The Viral Oncoprotein.

Authors:  Elisa Mazzoni; Ilaria Bononi; John Charles Rotondo; Chiara Mazziotta; Roberta Libener; Roberto Guaschino; Roberta Gafà; Giovanni Lanza; Fernanda Martini; Mauro Tognon
Journal:  J Oncol       Date:  2022-07-15       Impact factor: 4.501

7.  Diagnostic ability and its influenced factors of ultrasound-guided percutaneous pleural needle biopsy diagnosis for malignant pleural mesothelioma.

Authors:  Yuxin Zhang; Jiaxin Tang; Xinghua Zhou; Wuxi Chen; Shiyu Zhang; Yuqin Li; Dazhi Zhou; Liantu He; Qing Tang
Journal:  Front Surg       Date:  2022-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.